Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics

Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics

Summary: Background: Many repurposed drugs have progressed rapidly to Phase 2 and 3 trials in COVID19 without characterisation of Pharmacokinetics /Pharmacodynamics including safety data. One such drug is nafamostat mesylate. Methods: We present the findings of a phase Ib/IIa open label, platform r...

Full description

Bibliographic Details
Main Authors: Tom M. Quinn, Erin E. Gaughan, Annya Bruce, Jean Antonelli, Richard O'Connor, Feng Li, Sarah McNamara, Oliver Koch, Claire MacKintosh, David Dockrell, Timothy Walsh, Kevin G. Blyth, Colin Church, Jürgen Schwarze, Cecilia Boz, Asta Valanciute, Matthew Burgess, Philip Emanuel, Bethany Mills, Giulia Rinaldi, Gareth Hardisty, Ross Mills, Emily Gwyer Findlay, Sunny Jabbal, Andrew Duncan, Sinéad Plant, Adam D.L. Marshall, Irene Young, Kay Russell, Emma Scholefield, Alastair F. Nimmo, Islom B. Nazarov, Grant C. Churchill, James S.O. McCullagh, Kourosh H. Ebrahimi, Colin Ferrett, Kate Templeton, Steve Rannard, Andrew Owen, Anne Moore, Keith Finlayson, Manu Shankar-Hari, John Norrie, Richard A. Parker, Ahsan R. Akram, Daniel C. Anthony, James W. Dear, Nik Hirani, Kevin Dhaliwal
Format: Article
Language:English
Published: Elsevier 2022-02-01
Series:EBioMedicine
Subjects:
Respiratory medicine
Infectious diseases
SARS-CoV-2/COVID-19
Nafamostat mesylate
Total manuscript word count
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396422000408

Internet

http://www.sciencedirect.com/science/article/pii/S2352396422000408

Similar Items